AKT1 and cancer: Data from our previous studies showed that PITPNM3 is a putative receptor for CCL18 on the surface of breast cancer cells and that it mediates the effects of CCL18 by activating both the ERK and Akt/GSK-3β signaling pathways in cancer cells [15].